P-01. DIAGNOSTIC AND PREDICTIVE VALUES OF 18F-FDG PET/CT METABOLIC PARAMETERS IN EGFR-MUTATED ADVANCED LUNG ADENOCARCINOMA/ Seung Hyeun Lee(Kyung Hee University Hospital)

P-02. WHO WILL MAINTAIN AS LONG-TERM RESPONDERS MORE THAN 3 YEARS WITH FIRST- OR SECOND-GENERATION EGFR TKI AMONG EGFR MUTANT NSCLC?/ Ja Hyun Yeo(Samsung Medical Center)

P-03. PEMBROLIZUMAB IN PRE-TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): IMPACT OF BLOOD-BASED BIOMARKERS ON SURVIVAL OUTCOMES/ Ana Ortega Franco(The Christie Nhs Foundation Trust)

P-04. PRIMARY RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE IN AN STK11/TP53/KRAS-MUTANT LUNG ADENOCARCINOMA WITH HIGH PD-L1 EXPRESSION/ Seung Hyeun Lee(Kyung Hee University Hospital)

P-05. ACQUIRED RESISTANCE MECHANISM OF EGFR-KDD AGAINST EGFR TKIS IN NSCLC/ Chaelin Lee(Seoul National University, Seoul, Republic Of Korea)

P-06. LXH254 IN COMBINATION WITH AURKA INHIBITORS IS EFFECTIVE AGAINST NRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) CELLS/ Siyeon Park(Seoul National University)

P-07. FIRST-LINE (1L) NIVOLUMAB + IPILIMUMAB IN ASIAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) IN CHECKMATE 227/ Jong-Seok Lee(Seoul National University Bundang Hospital)

P-08. THE CONTRADICTION OF EGFR MUTATIONS BETWEEN MEN AND WOMEN IN INDONESIA : LITERATURE REVIEWS/ Fikri Gemilang(Universitas Pembangunan Nasional Veteran, Yogyakarta, Indonesia)

P-09. COMPREHENSIVE EVALUATION OF THE CLINICAL UTILITY OF PLASMA EGFR TEST IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO FIRST-LINE EGFR INHIBITORS/ Hongsik Kim(Samsung Medical Center, Sungkyunkwan University School Of Medicine)

P-10. CONSOLIDATIVE HIGH-DOSE RADIOTHERAPY FOR OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER/ Hakyoung Kim(Korea University Guro Hospital, Korea University College Of Medicine, Seoul, Republic Of Korea)

P-11. LUNG CANCER IN THE PREGNANT WOMAN: TO TREAT OR NOT TO TREAT, THAT IS THE QUESTION/ Ramlah Ramlah(Universitas Gadjah Mada)

P-12. A RARE CASE OF LUNG ADENOCARCINOMA HARBORING V600 DELETION MUTATION/ Heae Surng Park(Ewha Womans University Seoul Hospital)

P-13. CYTOKINE PROFILE OF EGFR WILD AND MUTANT TYPE LUNG ADENOCARCINOMA CELL LINES AFTER DIFFERENT RADIATION DOSES./ Yun Hee Lee(Bucheon St Mary’s Hospital, College Of Medicine, The Catholic University Of Korea)

P-14. OVERCOMING ACQUIRED RESISTANCE TO EGFR INHIBITOR THROUGH MODULATION OF ERK/ Bo Mi Ku(Samsung Medical Center,)

P-15. TUMOR-ASSOCIATED IMMUNE CELL PROFILING REVEALS DISTINCT IMMUNE CHECKPOINT INHIBITOR OUTCOMES IN ADVANCED NON-SMALL CELL LUNG CANCER/ Bo Mi Ku(Samsung Medical Center,)

P-16. IMPACT OF PRE-TREATMENT AXL EXPRESSION ON EGFR-TKI EFFICACY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION/ Akihiro Yoshimura(Kyoto Prefectural University Of Medicine, Kyoto, Japan)

P-17. DIAGNOSTIC EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER WITH SPECIMENS OF BODY CAVITY FLUIDS/ Lam Nguyen Son(Pham Ngoc Thach Hospital)

P-18. ANALYSIS OF THE IMPACT OF CHEMOTHERAPY IN LUNG CANCER PATIENTS IN INDONESIA: LITERATURE REVIEW/ Rahmat Fauzan(Padang State University)

P-19. ACQUIRED RESISTANCE MECHANISMS OF OSIMERTINIB IN PATIENTS WITH DE NOVO EGFRT790M-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)/ Ha-Ram Park(Seoul National University)

P-20. LUNG CANCER IN INDONESIA: HOW INDONESIA MEDICAL SCIENCES FIGHT WITH THIS ISSUE?/ Zulfa Saumia(Alumnus Universitas Gadjah Mada/ Independent Researcher)